GlycoMimetics Top Management

GlycoMimetics Management Team Effectiveness

The company has return on total asset (ROA) of (0.7399) % which means that it has lost $0.7399 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8266) %, meaning that it created substantial loss on money invested by shareholders. GlycoMimetics' management efficiency ratios could be used to measure how well GlycoMimetics manages its routine affairs as well as how well it operates its assets and liabilities. GlycoMimetics has a total of 64.53 Million outstanding shares. 30% of GlycoMimetics outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as GlycoMimetics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of GlycoMimetics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

GlycoMimetics Workforce Comparison

GlycoMimetics Insider Trading

GlycoMimetics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as GlycoMimetics often depends on how effective the management is. GlycoMimetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GlycoMimetics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GlycoMimetics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of GlycoMimetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GlycoMimetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of GlycoMimetics' management manipulating its earnings.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

If you are still planning to invest in GlycoMimetics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GlycoMimetics' history and understand the potential risks before investing.